# US 2023/0416224 A1 · Processes for preparing arimoclomol citrate and intermediates thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0416224 A1
- Document ID: US20230416224A1
- Status: Published application
- Kind: A1
- Application number: 18/037,461
- Filed: 2021-11-19
- Published: 2023-12-28
- Earliest claimed: 2020-11-19
- Assignees: Zevra Denmark A/S
- Applicants: Zevra Denmark A/S
- Inventors: Zhe Zhang; Mark Read; Elisabeth Vang Carstensen; Marco Poppe; Andreas Pelz
- Web page: https://patentgrep.com/patent/US20230416224A1

## CPC

- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- C07D 213/89: with hetero atoms directly attached to the ring nitrogen atom
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4816: {Wall or shell material}
- A61K 9/5047: {Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose}
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to a process for preparing arimoclomol, arimoclomol citrate and key intermediates, such as ORZY-01, thereof. The disclosure further relates to a process for preparing high purity arimoclomol citrate and methods of using the same.

## Claims

### Claim at position 1

1-157. (canceled)

### Claim 158

A process for preparing
wherein the process comprises the steps of:
1) mixing a compound of formula (I);
with a compound of formula (II) in a container;
in at least one first solvent at a first temperature to provide an intermediate, wherein the first solvent is selected from the group consisting of a polar protic solvent and a mixture of polar protic solvents, and the first temperature is within a range from about 70° C. to 100° C.;
2) wherein the intermediate formed during Step 1 is then reacted with sodium nitrite (NaNO2) at a second temperature in at least one second solvent to provide
wherein the at least one second solvent is selected from the group consisting of at least one chlorinated hydrocarbon, a mixture containing at least one chlorinated hydrocarbon, or a combination thereof, and
wherein the second temperature is within a range from about 0° C. to 15° C.

### Claim 159 (depends on 158)

A process for preparing arimoclomol citrate,
comprising the steps of:
performing the process of claim 158 to provide,
precipitating
with dibenzoyl L-tartaric acid to provide
reacting
with at least one base to form at least one free base of
and
d. precipitating the free base of
with citric acid to provide arimoclomol citrate.

### Claim 160 (depends on 159)

A pharmaceutical composition comprising:
wherein the composition is obtained by the process of claim 159.

### Claim 161 (depends on 160)

The pharmaceutical composition of claim 160, wherein the
(N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate)
comprises at least 98.0% of the pharmaceutical composition.

### Claim 162 (depends on 159)

A pharmaceutical kit comprising:
at least one pharmaceutical composition comprising,
wherein the composition is obtained by the process of claim 159;
and at least one set of instructions for use of the pharmaceutical composition in the treatment of Niemann Pick disease, type C.

### Claim 163 (depends on 161)

A method of treating Niemann Pick disease, type C in a subject in need thereof, wherein the subject is administered a therapeutically effective amount of the pharmaceutical composition of claim 161.

### Claim 164 (depends on 161)

A unit dosage form of the pharmaceutical composition of claim 161.

### Claim 165 (depends on 164)

The unit dosage form of claim 164, comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate at a dosage from about 50 mg to about 500 mg.

### Claim 166 (depends on 165)

The unit dosage form of claim 165, wherein the unit dosage form is selected from the group consisting of about 47 mg, about 62 mg, about 93 mg, or about 124 mg.

### Claim 167 (depends on 166)

A kit comprising a unit dosage form according to claim 166, and instructions for administration.

### Claim 168 (depends on 167)

The kit of claim 167, wherein the kit further comprises prescribing information for the method of treating Niemann Pick disease, type C in a subject in need thereof.

### Claim 169 (depends on 159)

A composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having the formula:
wherein the composition is obtained by the process of claim 159.

### Claim 170 (depends on 169)

The composition of claim 169, wherein the
(N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate)
comprises at least 98.0% of the composition.

### Claim 171 (depends on 170)

An oral formulation comprising the composition of claim 170 and at least one pharmaceutically acceptable excipient.

### Claim 172 (depends on 171)

The oral formulation of claim 171 comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate at a dosage of about 47 mg, about 62 mg, about 93 mg, or about 124 mg.

### Claim 173 (depends on 172)

A method of treating Niemann Pick disease, type C in a subject in need thereof, wherein the subject is administered a therapeutically effective amount of the oral composition of claim 172.
